The evolution of liver diseases, from fatty liver (AFLD, NAFLD) to steatohepatitis (NASH, ASH) may be caused by several different factors, including metabolic syndrome, dietary habits and alcohol consumption. Most liver diseases have an important inflammatory component playing a significant role in aggravating the liver condition, leading to fibrosis, cirrhosis and eventually cancer.
The new oral form of pentamidine developed by Verlyx, VLX103, combines several characteristics including anti-inflammatory activities, as well as hepatoselectivity. These characteristics give VLX103 a unique product profile for the treatment of important unmet medical needs in liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Verlyx is pursuing a development program for its lead product in NASH and ASH.